Fails 2 of 8 criteria. S4, compounding disclosure: The semaglutide and tirzepatide pages call the injections compounded, but no product page, answer, footer, policy or compliance statement says that compounded drugs are not FDA-approved. 1 more criterion also fails; see the table below.
At a glance
Renlo HealthTelehealth service
6/8criteria passed
Price
Semaglutide $199 a month, listed at $299; tirzepatide $269, listed at $399
Sells
compounded semaglutide, compounded tirzepatide, NAD+ injection, and 1 more
Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.
A telehealth platform selling compounded semaglutide and tirzepatide at one flat monthly price for every dose, plus NAD+ and glutathione injections, prescribed by a physician-led provider group. It names its filling pharmacy and a business address, and no page states that its compounded drugs are not FDA-approved.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSA licensed U.S. provider reviews each intake and prescribes only if the patient qualifies, and the compliance page names the provider group as Arora Health & Aesthetics, LLC, 300 Lenora Street, Seattle, WA 98121.Source: Renlo Health's website; Renlo Health's compliance page.
S2PASSThe start buttons point to the online-visit intake, the home page describes a free health assessment as the first step, and the product answers say no charge is made until a licensed provider reviews the intake and approves treatment.Source: Renlo Health's website; Renlo Health's semaglutide page.
S3PASSThe compliance page names the partner pharmacy as VialsRx, 6220 Westpark Dr, Houston, TX 77057, a state-licensed 503A compounding pharmacy, and each product page says prescriptions are filled by it.Source: Renlo Health's compliance page; Renlo Health's semaglutide page.
S4FAILThe semaglutide and tirzepatide pages call the injections compounded, but no product page, answer, footer, policy or compliance statement says that compounded drugs are not FDA-approved.Source: Renlo Health's semaglutide page; Renlo Health's tirzepatide page; Renlo Health's compliance page; Renlo Health's is compounded semaglutide safe article.
S5FAILNo certificate of analysis or lot document is published on the product pages, the compliance page or the policies.Source: Renlo Health's semaglutide page; Renlo Health's compliance page; Renlo Health's website.
S6PASSRenlo Health LLC, 13802 North Scottsdale Road, Suite 151, Scottsdale, AZ 85254, printed in the terms, the privacy policy, the privacy notice and the refund policy. The terms name Delaware law.Source: Renlo Health's terms of service page; Renlo Health's privacy policy; Renlo Health's refund policy.
S7PASSCompounded semaglutide at $199 a month against a struck-through $299, and compounded tirzepatide at $269 a month against a struck-through $399, each the same at every dose and billed monthly with medication, supplies and shipping included. NAD+ injection at $179 a month and glutathione injection at $129 a month. A banner offers $50 off the first order with a code.Source: Renlo Health's semaglutide page; Renlo Health's tirzepatide page; Renlo Health's NAD+ page; Renlo Health's glutathione page; Renlo Health's website.
S8PASSNo FDA warning letter names Renlo Health or Renlo Health LLC, and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+ injection, glutathione injection.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.